Exdensur evaluation in New York

Yes. Exdensur is FDA approved as add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and children age 12 or older. It is not a rescue medicine for an acute attack. Its healthcare-provider administration and six-month schedule require a prescribing and follow-up plan.

The US indication is add-on maintenance treatment for adults and children age 12 or older with severe asthma and an eosinophilic phenotype. This US indication does not include allergies in general, eczema or COPD. Confirm optimized inhaled care, attacks and biomarkers with the clinician.

The labeled dose is 100 mg by subcutaneous injection once every six months. A healthcare provider must administer Exdensur. Before scheduling, settle diagnosis, the order, authorization, medication delivery, storage and the clinic’s ability to administer and manage a reaction.

Exdensur does not treat acute bronchospasm or status asthmaticus. Do not abruptly reduce corticosteroids or stop other asthma medicines. Hypersensitivity reactions and helminth infection precautions require review. Follow the asthma emergency plan for severe or rapidly worsening breathing symptoms.

As of October 9, 2026, GSK lists Exdensur among its products available in the United States. Its US label requires a healthcare-provider injection every six months for eligible patients with severe eosinophilic asthma. Commercial availability does not confirm the chosen clinic’s supply or ability to administer it; arrange those details before the appointment.

Exdensur does not treat acute bronchospasm or status asthmaticus. Do not abruptly reduce corticosteroids or stop other asthma medicines. Hypersensitivity reactions and helminth infection precautions require review. Follow the asthma emergency plan for severe or rapidly worsening breathing symptoms. Track symptoms and exacerbations throughout the six-month interval. If a dose is missed, the label calls for administration as soon as possible and a new six-month schedule from the actual dose. Coordinate that decision with the provider. Do not self-inject or use this schedule for another biologic.

A consultation starts with the clinical review and required records. Treatment or a procedure depends on suitability, the actual order, safety checks, staff, supplies and any authorization; booking does not guarantee a dose or procedure that day. The labeled dose is 100 mg by subcutaneous injection once every six months. A healthcare provider must administer Exdensur. Before scheduling, settle diagnosis, the order, authorization, medication delivery, storage and the clinic’s ability to administer and manage a reaction.

Confirm the exact service at the selected clinic before booking. Evaluation, prescribing, testing, training and administration are separate capabilities. Confirm the exact clinic, product and appointment: evaluation, prescribing, training and administration are separate services. Bring an outside order before relying on administration at Nao. Drug, visit and administration benefits may be separate; manufacturer assistance does not guarantee insurance approval. Arrange the pharmacy, shipment and next review with the treating team. Local stock or same-day dosing is not established by approval. FDA approval and a current label do not establish commercial stock at a particular pharmacy or Nao clinic.

Before treatment starts, confirm the diagnosis, the intended benefit, the exact treatment and who will coordinate ongoing care. The labeled dose is 100 mg by subcutaneous injection once every six months. A healthcare provider must administer Exdensur. Before scheduling, settle diagnosis, the order, authorization, medication delivery, storage and the clinic’s ability to administer and manage a reaction.

Prepare the relevant dated records, current medicine list and your main questions, and confirm any treatment-specific instructions before attending. Bring lung-function reports, eosinophil results, inhalers, steroid courses, hospital records and previous biologic history. Tell the team about infections, helminth exposure, pregnancy plans or prior reactions. The first evaluation may identify missing records or require specialist care before a dose is ordered.

Agree on the next review, how response and safety will be checked, and who to contact for symptoms, missed treatment or a refill problem. Track symptoms and exacerbations throughout the six-month interval. If a dose is missed, the label calls for administration as soon as possible and a new six-month schedule from the actual dose. Coordinate that decision with the provider. Do not self-inject or use this schedule for another biologic.

Contact the prescribing team and the insurer promptly, before the next treatment date. Ask for the written reason, authorization dates, missing records and the appeal instructions for your plan. Tell the prescriber when the next dose is due so a treatment gap can be assessed. Do not change the dose or substitute another medicine yourself. An appeal or manufacturer assistance request does not establish approval. Appeal routes and deadlines depend on the plan and the kind of denial; New York’s fully insured plan rules do not cover every type of insurance.